EUCTR2009-018014-20-GB进行中（未招募）不适用
A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer - COSAK
Common Services Agency0 个研究点目标入组 130 人开始时间: 2010年3月18日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histopathologically confirmed renal cell carcinoma with measurable metastases on CT/MRI imaging.
- •- Radiological progressive disease on first line VEGF targeted therapy. First line VEGF targeted therapy must consist either pazopanib, sunitinib, sorafenib, bevacizumab. Patients treated with initial interferon prior to TKI exposure, or in combination with bevacizumab, are acceptable.
- •- Evidence of measurable disease (ie, =1 malignant tumor mass that can be accurately measured in at least 1 dimension = 20 mm with conventional computerized tomography [CT] scan or Magnetic Resonance Imaging [MRI], or =10 mm with spiral CT scan using a 5 mm or smaller contiguous reconstruction algorithm). Bone lesions, ascites, peritoneal carcinomatosis or miliary lesions, pleural or pericardial effusions, lymphangitis of the skin or lung, cystic lesions, or irradiated lesions are not considered measurable.
- •- Adequate organ function as defined by the following criteria:
- •- Total serum bilirubin =1.5 x ULN (patients with Gilbert’s disease exempt),
- •- Serum transaminases <2.5 x ULN (x5 in the presence of liver metastasis
- •- Serum creatinine =1.5 x ULN,
- •- Absolute neutrophil count (ANC) =1000/mm3 without growth factor support,
- •- Platelets = 100,000/mm3
- •- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
- •- Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
- •- ECOG performance status of 0, 1 or 2.
- •- Life expectance >12 weeks
- •- At least 2 weeks since the end of prior systemic treatment (sunitinib, pazopanib, sorafenib) radiotherapy, or surgical procedure with resolution of all treatment-related toxicity to NCI CTCAE Version 3.0 grade =1 or back to baseline except for alopecia or hypothyroidism. A 4 week gap should exist since bevacizumanb +INF.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Congestive heart failure, myocardial infarction or coronary artery bypass graft in the previous six months, ongoing severe heart disease.
- •- Pregnancy or breastfeeding. Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. Male patients must be surgically sterile or agree to use effective contraception.
- •- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormally that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- •- Untreated unstable brain or meningeal metastases or tumour. Patients with radiological evidence of stable brain metastases are eligible providing that they are asymptomatic and either do not require corticosteroids or have been treated with corticosteroids, with clinical and radiological evidence of stabilisation at least 10 days after discontinuation of steroids.
- •- Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio < 1.5.
- •- History of significant gastrointestinal impairment, as judged by the investigator, that would significantly affect the absorption of cediranib
- •- Patients with a recent history of poorly controlled hypertension with resting blood pressure >150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy, or patients who are requiring maximal doses of calcium channel blockers to stabilize blood pressure
- •- Any evidence of severe of uncontrolled diseases eg, unstable or uncompensated respiratory, hepatic or renal disease.
- •- Mean QTc with Bazetts correction >480msec in screening ECG or history of familial long QT syndrome
- •- Any evidence of interstitial lung disease (bilateral, diffuse, parenchymal lung disease).
- •- Significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks)
- •- Recent (<14 days) major thoracic or abdominal surgery prior to entry into the study, or a surgical incision that is not fully healed
- •- Unresolved toxicity = CTC grade 2 (except alopecia) from previous anti-cancer therapy.
- •- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ or localised controlled prostate cancer) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of the primary cancer of interest from a target lesion.
- •- Known inherited or acquired immunodeficiency
- •- Known risk of the patient transmitting HIV, hepatitis B or C via infected blood
- •- Involvement in the planning and conduct of the study
- •- Previous enrolment or randomisation of treatment in the present study.
- •- Treatment with an investigational (not including VEGF TKIs such as pazopanib) drug within 30 days prior to the first dose of cediranib.
- •- Other concomitant anti-cancer therapy (including LHRH agonists) except steroids
- •- Previous bone marrow transplant
- •- Study drugs should be permanently discontinued in patients with the following conditions:
- •- Gastrointestinal perforation or wound dehiscence requiring medical interven
研究者
相似试验
进行中（未招募）
1 期
Clinical trial testing the drug cediranib(AZD2171)against placebo with cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancersbiliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas)MedDRA version: 17.0 Level: LLT Classification code 10004595 Term: Bile duct cancer NOS System Organ Class: 100000004864MedDRA version: 17.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864MedDRA version: 17.0 Level: LLT Classification code 10017617 Term: Gallbladder cancer non-resectable System Organ Class: 100000004864EUCTR2009-013408-30-GBniversity College London124
进行中（未招募）
不适用
A clinical trial of a drug called Cediranib in the treatment of patients with a type of cancer called alveolar soft part sarcomaMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Alveolar soft part sarcomaMedDRA version: 14.1Level: HLTClassification code 10001883Term: Alveolar soft part sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021163-33-ESThe Institute of Cancer Research / The Royal Marsden NHS Foundation Trust36
进行中（未招募）
1 期
Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical CancerEUCTR2016-004215-13-GBThe Clatterbridge Cancer Centre NHS Foundation108
已完成
2 期
COMICE: A Randomised Double Blind Placebo Controlled Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical CancerCancerCervical cancerISRCTN10841582The Clatterbridge Cancer Centre NHS Foundation Trust74
招募中
2 期
A trial of cediranib in the treatment of patients with alveolar soft part sarcomaAlveolar soft part sarcomaACTRN12612000020886The Institute of Cancer Research / Royal Marsden Hospital NHS Foundation Trust (UK)36